Zacks: Analysts Anticipate The Medicines Company (NASDAQ:MDCO) to Announce -$0.66 Earnings Per Share

Equities research analysts expect The Medicines Company (NASDAQ:MDCO) to report ($0.66) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for The Medicines’ earnings, with estimates ranging from ($0.68) to ($0.62). The Medicines posted earnings of ($0.63) per share in the same quarter last year, which would suggest a negative year over year growth rate of 4.8%. The firm is expected to announce its next earnings report on Wednesday, August 7th.

According to Zacks, analysts expect that The Medicines will report full year earnings of ($2.57) per share for the current fiscal year, with EPS estimates ranging from ($2.83) to ($2.40). For the next financial year, analysts anticipate that the firm will report earnings of ($2.24) per share, with EPS estimates ranging from ($2.80) to ($1.85). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover The Medicines.

The Medicines (NASDAQ:MDCO) last released its earnings results on Thursday, April 25th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.09). During the same period last year, the company earned ($0.76) earnings per share. The Medicines’s revenue for the quarter was down 100.0% compared to the same quarter last year.

Several research firms have commented on MDCO. Roth Capital set a $14.00 target price on Enphase Energy and gave the stock a “buy” rating in a report on Thursday, March 21st. Bank of America reaffirmed a “buy” rating and set a $43.00 price target (up from $36.00) on shares of The Medicines in a report on Tuesday. B. Riley set a $61.00 price target on The Medicines and gave the company a “buy” rating in a report on Tuesday, May 28th. Goldman Sachs Group reaffirmed a “buy” rating and set a $68.00 price target on shares of Total in a report on Friday, April 26th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $90.00 price target (up from $85.00) on shares of The Medicines in a report on Friday, April 26th. One research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $61.70.

In other news, Director Alexander J. Denner bought 160,000 shares of the stock in a transaction on Monday, May 20th. The shares were bought at an average price of $34.50 per share, with a total value of $5,520,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alexander J. Denner bought 85,000 shares of the stock in a transaction on Thursday, May 30th. The stock was purchased at an average cost of $34.83 per share, for a total transaction of $2,960,550.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 726,000 shares of company stock worth $24,737,140. Corporate insiders own 10.29% of the company’s stock.

A number of hedge funds have recently bought and sold shares of MDCO. Crossmark Global Holdings Inc. bought a new position in The Medicines during the second quarter valued at approximately $259,000. Marshall Wace North America L.P. bought a new position in The Medicines during the first quarter valued at approximately $1,897,000. Westfield Capital Management Co. LP boosted its stake in The Medicines by 14.9% during the first quarter. Westfield Capital Management Co. LP now owns 5,290,481 shares of the company’s stock valued at $147,869,000 after buying an additional 685,762 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in The Medicines by 10.3% during the first quarter. First Eagle Investment Management LLC now owns 492,873 shares of the company’s stock valued at $13,776,000 after buying an additional 45,838 shares during the last quarter. Finally, CIBC Private Wealth Group LLC boosted its stake in The Medicines by 27.6% during the first quarter. CIBC Private Wealth Group LLC now owns 15,468 shares of the company’s stock valued at $432,000 after buying an additional 3,350 shares during the last quarter.

The Medicines stock traded up $0.63 during mid-day trading on Thursday, hitting $38.44. The company had a trading volume of 1,789,995 shares, compared to its average volume of 1,281,998. The business has a 50 day simple moving average of $36.05. The Medicines has a 12 month low of $16.69 and a 12 month high of $41.57. The company has a market capitalization of $2.85 billion, a P/E ratio of -13.21 and a beta of 1.08.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels.

See Also: What is Call Option Volume?

Get a free copy of the Zacks research report on The Medicines (MDCO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.